We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oxford BioMedica Announces Novartis Collaboration
News

Oxford BioMedica Announces Novartis Collaboration

Oxford BioMedica Announces Novartis Collaboration
News

Oxford BioMedica Announces Novartis Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oxford BioMedica Announces Novartis Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Under the terms of the agreement, Oxford BioMedica will also provide certain process development services and expects to receive between £2.5 million and £4 million from Novartis over the next 12 months.

Oxford BioMedica will be responsible for manufacturing several batches of a lentiviral vector encoding CTL019 technology.  This vector will be used to transduce patients’ immune cells (T-cells) in an ex vivo process before they are re-infused into patients.  CTL019 targets a protein called CD19 that is associated with a number of B-cell malignancies including chronic lymphocytic leukemia, B-cell acute lymphocytic leukaemia and diffuse large B-cell lymphoma.

John Dawson, Chief Executive Officer of Oxford BioMedica, commented: “We are delighted to be working with Novartis to support a key immunotherapy programme. The strategic investment in our specialist manufacturing capabilities is a pivotal step towards building a financially self-sustaining business and this collaboration is an example of how we can commercialise our expertise.”

Advertisement